Abstract Sildenafil is used to treat pulmonary hypertension (PAH) in infants with congenital diaphragmatic hernia (CDH). However, data to guide sildenafil dosing and weaning are limited. This is concerning in light of a recent report describing increased risk associated with high-dose sildenafil regimens in non-CDH PAH. A retrospective cohort study of sildenafil usage, dosing, and weaning in infants with CDH was conducted at the authors' institution. The findings show that 17 % (19/122) of infants were discharged receiving sildenafil at a median dose of 8 mg/ kg/day (range 2.91-5.78 mg/kg/day). The weaning rate was 0.1 mg/kg/week (range 0.01-0.5 mg/kg/week). The infants ceased therapy after a median of 343 days. At the age of 1 year, 29 % were receiving sildenafil at a dose higher than 1.5 mg/kg/day. One infant died of severe PAH. Sildenafil therapy at discharge is common in severe CDH. Variation in dosing and weaning rates highlights the need for standardized assessment and treatment of PAH after discharge to optimize the benefits and minimize the adverse effects of sildenafil.
Pulmonary hypertension (PAH) is an important cause of morbidity and mortality in congenital diaphragmatic hernia (CDH) [2] . In the acute setting, sildenafil, a phosphodiesterase-5 inhibitor, is used as a synergistic pulmonary vasodilator with inhaled nitric oxide (iNO) to treat PAH in CDH or to allow weaning of iNO [6] . Sildenafil therapy may itself subsequently be weaned if it is perceived to be no longer necessary [4] .
In our unit, sildenafil is used for babies with severe PAH. It is started either as an adjunct to iNO for infants with ongoing echocardiographic evidence of severe PAH and right ventricular dysfunction or to facilitate iNO weaning.
The literature has minimal data regarding appropriate dosing of sildenafil at discharge or weaning regimens and none relating to CDH specifically. More recently, a doseranging study of children with non-CDH PAH by Barst et al. [1] observed increased mortality and side effects in children receiving high-dose compared with medium-dose sildenafil during a 2-year follow-up period. For the lowest weight group in this study (8-20 kg), the high-dose regimen (20 mg three times per day) equaled 3-7.5 mg/kg/day, whereas the medium dose equated with a dosage range of 1.5-3.75 mg/kg/day. In response to this study, the Food and Drug Administration (FDA) issued a warning recommending that sildenafil should not be prescribed for children with PAH between the ages of 1 and 17 years [3] .
In light of these reports and in the absence of data relating to sildenafil use in CDH, we aimed to determine the proportion of CDH patients discharged receiving sildenafil as well as sildenafil dosing, duration, and rate of weaning at our institution.
Methods
A retrospective cohort study was conducted. All CDH patients managed at our institution between September 2005 and September 2012 were identified from our departmental database. Sildenafil dosing and patient weights were obtained from the discharge summary and subsequent outpatient case records to enable a daily dosage calculation (mg/kg/day) using the most recent available weight. The rate of sildenafil weaning and the duration of therapy also were obtained. In addition, the time required for weaning to a dose lower than 1.5 mg/kg/day was calculated. This threshold was chosen based on recent concerns of higher dosing regimens [1] .
The doses of sildenafil used at our institution were in accordance with a local formulary [7] (maximum dosing, 2-3 mg/kg/dose, 3 to 6 hourly). Typically, sildenafil is started at a dose of 1 mg/kg every 6 h as an inpatient therapy to facilitate weaning of iNO. The decision to start sildenafil and any subsequent dose increases were made by the treating neonatal clinical team based on clinical and echocardiographic findings suggestive of ongoing severe PAH (i.e., elevated tricuspid regurgitation velocity or bidirectional right-to-left ductal shunting, indicating pulmonary artery pressures (PAPs) equal to systemic arterial pressure or higher). Infants with CDH managed in our unit receive regular functional echocardiograms for assessment of PAH and cardiac function.
If considered necessary, increases in dosages were made by 0.5 mg/kg/day at a minimum of 48-h intervals up to maximum recommended dosage. Any variation in timing of dose adjustment between patients may have reflected differences in severity of PAH, concomitant therapies, or physician discretion, as well as the absence of formal guidelines.
Sildenafil therapy was continued at discharge if PAH persisted at that time, with weaning thereafter. Weaning was performed in the outpatient setting by the Paediatric Cardiologist Team on the basis of serial clinical evaluation, electrocardiography, and echocardiographic findings to assess improvement of PAH.
Results
During the study period, 112 eligible infants with CDH were managed at our institution, 19 (17 %) of whom were discharged receiving sildenafil. Details of sildenafil weaning were available for 17 infants. The CDH was right-sided in 4 infants and left-sided in 13 infants. All the infants who started receiving sildenafil as inpatients survived to discharge and still were receiving sildenafil at the time of discharge.
Group demographic and sildenafil weaning data are shown in Table 1 . At discharge, the median weight was 4.56 kg (range 2.91-5.78 kg), and the median dose of sildenafil was 7.9 mg/kg/day (range 1.2-18.9 mg/kg/day).
The sildenafil dosage was weaned for all infants after discharge at a median rate of 0.1 mg/kg/week (range 0.01-0.5 mg/kg/week). At discharge, 16 infants were receiving the maximal sildenafil dosage and were weaned thereafter. One infant had an increase in dosage after discharge and achieved a maximal dosage of sildenafil on day 257 (discharge dosage, 3 mg/kg/day; maximal dose, 9.4 mg/kg/day; subsequently weaned to cessation after 562 days).
During the study period, 10 infants ceased receiving sildenafil. The median time to cessation was 343 days (range 105-671 days), and the median time required to achieve a dose lower than 1.5 mg/kg/day was 226 days (range 0-562 days). The remaining 7 infants continued to receive a higher dose during the study period (median dose, 5.4 mg/kg/day; range 3.8-8.9 mg/kg/day). The median follow-up period was 186 days (range 55-644 days).
The sildenafil dosage was halved for 15 infants at a median time of 192 days (range 88-577 days). Only two infants continued to receive more than half the starting dose at the latest clinic review (both were younger than 100 days). The discharge doses were weaned respectively from 9.8 to 8.9 mg/kg/day at 92 days and from 7.7 to 5.4 mg/kg/day at 55 days.
One infant died of complications from severe PAH at 192 days. This patient was not atypical of the group. Discharged at 90 days receiving a dose of 3.7 mg/kg/day, this patient subsequently was weaned to 2.4 mg/kg/day and to 0.05 mg/kg/week at the time of death.
At 1 year of age, five infants (29 %) still were receiving sildenafil at a dosage higher than 1.5 mg/kg/day (Fig. 1) . Seven infants had not yet reached the 2-year follow-up visit. For the nine infants with complete growth parameters available, the median growth velocity was 120 g/week (range 39-215 g/week).
Five infants (29 %) were discharged receiving low-flow oxygen. The median oxygen requirement was 0.5 L/min (range 0.05-0.8 L/min). During the study follow-up period, three infants were weaned off oxygen within a range of 342-577 days. The median sildenafil dosage at discharge for those infants requiring oxygen was 3.7 mg/kg (range 1.2-18.2 mg/kg).
Discussion
Nearly one-fifth of the infants with CDH in our series received sildenafil after hospital discharge as treatment of PAH. This usage rate is comparable with that of other institutions managing infants with CDH [4] . We provide the first report of sildenafil dosing after discharge. All infants had their sildenafil dosage weaned after discharge but continued to receive treatment for 3-22 months. The rate of weaning and the duration of therapy were comparable with those for infants who had bronchopulmonary dysplasia (BPD)-associated PAH reported by Mourani et al. [5] . In the latter study, the dose ranges were 1.5-8 mg/kg, and the median duration of treatment was 241 days.
The dosages used for our cohort were comparable with those of prior reports and within current prescribing regimens [4, 6] . However, the dosage and rate of postdischarge weaning varied significantly within our cohort. This variation may reflect variable illness severity or predischarge weaning in some infants, but it also highlights the lack of current data to guide uniform sildenafil use and weaning in CDH.
Weight gain also contributes to relative dose weaning. Infants with poor growth may therefore be exposed to higher relative dosing for longer periods, whereas optimization of nutrition and growth may indirectly produce faster weaning of the relative sildenafil dosage.
Our study was prompted in part by a recent report by Barst et al. [1] , which raised concerns of increased side effects and mortality associated with high-dose, long-term (2 year) sildenafil therapy for children with non-CDH PAH and in part by the FDA response advising against sildenafil use for children with PAH [3] . Based on these findings, the authors recommended using a medium dosage regimen equal to a dose range of 1.5-3.75 mg/kg/day in a weight group of 8-20 kg.
The majority of infants in our series were discharged receiving a dosage higher than 1.5 mg/kg/day and required a median of 7.5 months for weaning below this level. Nearly one-third remained on a dose higher than 1.5 mg/kg/day at the age of 1 year. This may raise concerns regarding the potential adverse effects of current sildenafil use in our population of CDH infants. However, differences between study populations may prevent direct application of the findings reported by Barst et al. [1] to our cohort. Barst et al. [1] study investigated the treatment of naive individuals, whereas sildenafil was started for the infants in our series after a period of iNO therapy. Most of the infants in our study weighed less than 8 kg, whereas all the infants in Barst et al. [1] study weighed more than 8 kg.
Furthermore, Barst et al. [1] studied older children with non-CDH PAH, which is likely to be chronic and lifelimiting, requiring prolonged therapy with associated sustained side-effect risks. In CDH, however, PAH usually improves, and as our study demonstrated, therapy may be weaned, thereby potentially minimizing adverse events. The retrospective nature and small sample size of our series prevented full assessment of potential side effects and adverse events. Notably, however, no infant had treatment stopped for this reason, and the one infant who died was not receiving the highest sildenafil dosage. To resolve the question whether the concerns raised by Barst et al. [1] apply to a younger, lighter group of infants with CDH requires further study. In the meantime, our current practice aims to limit the future discharge dosage to 1.5 mg/kg/ day.
Could sildenafil be weaned more quickly in CDH? Ideally, dosage would be optimized regularly based on accurate assessment of PAP and the secondary effects on cardiac function, functional status, and growth. In current practice, clinical assessment is combined with serial echocardiography. However, PAP may be difficult to quantify accurately using echocardiography, particularly in Postdischarge growth velocity (g/week) (n = 9) 120 3.9-215
Parenthetical numbers refer to the number of infants from whom data was obtained Days post discharge % of patients with sildenafil dose > 1.5 mg/kg/day Fig. 1 Percentage of patients receiving a sildenafil dosage higher than 1.5 mg/kg/day after discharge the absence of a tricuspid regurgitation. Improved noninvasive assessment of PAH and cardiac function would inform understanding concerning the natural history of PAP in CDH. Plasma biomarkers of PAH and new echocardiographic methods, such as tissue Doppler imaging, could hold potential for this purpose and may merit future study. With improved assessment of PAH after discharge, we hope for the development of standardized guidelines for dosing, PAH assessment, and sildenafil weaning after discharge as potential means of shortening the course of treatment and avoiding doserelated side effects.
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